{"id":"a0bb956c-fcf2-4374-b893-42388bad22be","name":"MMI (Medical Microinstruments)","slug":"mmi-symani","description":"Italian-founded surgical robotics company developing the [Symani](/models/symani-surgical-system) Surgical System, the first robotic platform for open soft-tissue microsurgery. MMI's NanoWrist instruments are the world's smallest wristed surgical robotic instruments, enabling tremor filtration and motion scaling for procedures on vessels as small as 0.3mm. Founded in 2015 near Pisa, Italy, MMI received FDA De Novo authorization in April 2024 and CE mark in 2019, with ~1,000 clinical cases completed in Europe.","status":null,"founded":2015,"hq":"Jacksonville, Florida, USA","fundingTotal":"211000000","type":null,"reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[],"keyFacts":[{"label":"CEO","value":"Mark Toland"},{"label":"Founded","value":"2015 near Pisa, Italy"},{"label":"HQ","value":"Jacksonville, Florida (US redomicile 2022); R&D and manufacturing in Pisa, Italy"},{"label":"Product","value":"Symani Surgical System — robotic microsurgery platform with NanoWrist instruments (world's smallest wristed surgical robotic instruments, 7 DOF, tremor filtration, motion scaling)"},{"label":"FDA status","value":"FDA De Novo Authorization (April 2024) — only commercially available platform in the U.S. for reconstructive microsurgery"},{"label":"CE mark","value":"Received CE mark in Europe (2019); commercially available in Europe and parts of Asia Pacific"},{"label":"Clinical cases","value":"~1,000 clinical cases in the EU; first U.S. clinical cases completed in 2024"},{"label":"Funding","value":">$200M total ($2M seed 2016, $24M Series A 2018, $75M Series B 2022, $110M Series C 2024)"},{"label":"Financial stage","value":"Growth — commercial stage with FDA authorization, expanding globally"},{"label":"Manufacturing","value":"Symani manufactured in Pisa, Italy"},{"label":"Key investors","value":"Fidelity Management & Research Company (Series C lead), Deerfield Management (Series B lead), RA Capital, Andera Partners, Fountain Healthcare, Panakès Partners, Wellington Partners"},{"label":"REMIND study","value":"First robotic microsurgical study in Alzheimer's patients (IDE approved Nov 2025, first patient treated May 2026)"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"createdAt":"2026-07-18T03:17:11.021Z","updatedAt":"2026-07-18T05:10:33.803Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/mmi-symani","url":"https://registry.deploy.report/companies/mmi-symani","name":"MMI (Medical Microinstruments)","description":"Italian-founded surgical robotics company developing the [Symani](/models/symani-surgical-system) Surgical System, the first robotic platform for open soft-tissue microsurgery. MMI's NanoWrist instruments are the world's smallest wristed surgical robotic instruments, enabling tremor filtration and motion scaling for procedures on vessels as small as 0.3mm. Founded in 2015 near Pisa, Italy, MMI received FDA De Novo authorization in April 2024 and CE mark in 2019, with ~1,000 clinical cases completed in Europe.","identifier":"a0bb956c-fcf2-4374-b893-42388bad22be","foundingDate":"2015","address":"Jacksonville, Florida, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"claimed-not-verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":0,"primary_source_types":[]}}}